Related Experiment Video
Updated: Jan 10, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
TREX1, a predator for treating MSI-H tumors?
Elena Benidovskaya1, Joséphine Deneft1, Marc Van den Eynde1,2,3
1IREC MIRO-ONCO, Laboratory of Oncology, UCLouvain, Brussels, Belgium.
Abstract:
Immunotherapy has revolutionized cancer treatment; yet, a subset of patients with microsatellite instability-high (MSI-H) tumors fails to respond to treatment despite their elevated tumor mutational burden and immunogenic potential. In a recent study, Xu et al. uncover a key mechanism of immune evasion in MSI-H tumors mediated by the exonuclease TREX1, which degrades cytosolic DNA and suppresses activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING)-type I interferon pathway. Loss of TREX1 restores cytosolic DNA sensing, promotes CD8+ T and NK cell infiltration, and enhances antitumor immunity. These findings highlight TREX1 as a potential therapeutic target to overcome resistance to immune checkpoint blockade.
Insights
Microsatellite instability-high (MSI-H) tumors can evade immunotherapy. A study reveals the exonuclease TREX1 degrades DNA, suppressing immune responses. Inhibiting TREX1 may improve cancer immunotherapy effectiveness.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immunotherapy has transformed cancer care, but some patients with microsatellite instability-high (MSI-H) tumors do not respond.
- These MSI-H tumors possess high mutation rates and immunogenic potential, yet exhibit immune evasion.
Purpose of the Study:
- To investigate the mechanisms of immune evasion in MSI-H tumors.
- To identify potential therapeutic targets for overcoming immunotherapy resistance in MSI-H cancers.
Main Methods:
- The study focused on the role of the exonuclease TREX1 in regulating cytosolic DNA and immune responses.
- Experiments involved analyzing TREX1's function in degrading cytosolic DNA and its impact on the cGAS-STING pathway.
- Assessed the effects of TREX1 loss on immune cell infiltration and antitumor immunity.
Main Results:
- TREX1 degrades cytosolic DNA, which suppresses the activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway and type I interferon production.
- Loss of TREX1 function restores cytosolic DNA sensing, leading to enhanced immune cell activity.
- TREX1 deficiency promotes the infiltration of CD8+ T cells and NK cells, boosting antitumor immunity.
Conclusions:
- TREX1 is a key mediator of immune evasion in MSI-H tumors by suppressing innate immune sensing.
- Targeting TREX1 presents a promising strategy to enhance the efficacy of immune checkpoint blockade therapy.
- Restoring immune surveillance through TREX1 inhibition could overcome resistance in a subset of cancer patients.
